β2-glycoprotein I and oxidative inflammation in early atherogenesis: A progression from innate to adaptive immunity?

Autoimmunity Reviews

Volumn 12, Issue 2, 2012, Pages 241-249

  Matsuura, Eiji ^a   Lopez, Luis R ^b   Shoenfeld, Yehuda ^c   Ames, Paul R J ^d  

^a OKAYAMA UNIVERSITY   (Japan)

^b Division of Medicine   (United States)

^c TEL AVIV UNIVERSITY   (Israel)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

2 Glycoprotein I ( 2GPI); Atherosclerosis; Immune system; Inflammation; Oxidative stress

Indexed keywords

ANION; BETA2 GLYCOPROTEIN 1; CANAKINUMAB; CASPASE; CHOLESTEROL; CYTOKINE RECEPTOR ANTAGONIST; CYTOPLASMIC RECEPTOR; EPITOPE; INFLAMMASOME; INTERLEUKIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID; PLASMA PROTEIN; PYRINDAMYCIN A; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILOACEPT; ROSUVASTATIN; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOINFLAMMATORY DISEASE; COMPLEX FORMATION; CYTOPLASM; FIBRINOLYSIS; HEART FAILURE; HUMAN; INFLAMMATION; INNATE IMMUNITY; LIPID PEROXIDATION; NONHUMAN; OXIDATIVE STRESS; PLEIOTROPY; REVIEW; SIGNAL TRANSDUCTION; STIMULUS RESPONSE; TISSUE INJURY;

ADAPTIVE IMMUNITY; ANIMALS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASES; BETA 2-GLYCOPROTEIN I; HUMANS; IMMUNITY, INNATE; INFLAMMASOMES; INFLAMMATION; INTERLEUKIN-1; LIPID PEROXIDATION; LIPOPROTEINS, LDL; MACROPHAGE ACTIVATION; MACROPHAGES; OXIDATION-REDUCTION; SIGNAL TRANSDUCTION;

EID: 84870247810     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.04.003     Document Type: Review

References (56)

1. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
2. Hansson G.K. Inflammation, atherosclerosis and coronary artery disease. N Engl J Med 2005, 352:1685-1695.
3. Matsuura E., Kobayashi K., Tabuchi M., Lopez L.R. Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis. Prog Lipid Res 2006, 45:466-486.
4. Matsuura E., Hughes G.R.V., Khamashta M.A. Oxidation of LDL and its clinical implication. Autoimmun Rev 2008, 7:558-566.
5. Hartvigsen K., Chou M.Y., Hansen L.F., Shaw P.X., Tsimikas S., Binder C.J., et al. The role of innate immunity in atherogenesis. J Lipid Res 2009, 50:S388-S393.
6. Lundberg A.M., Hansson G.K. Innate immune signals in atherosclerosis. Clin Immunol 2010, 134:5-24.
7. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
8. Bauernfeind F.G., Horvath G., Stutz A., Alnemri E.S., MacDonald K., Speert D., et al. NF-kB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol 2009, 183:787-791.
9. Meylan E., Tschopp J., Karin M. Intracellular pattern recognition receptors in the host responses. Nature 2006, 442:39-44.
10. Stutz A., Golenbock D.T., Latz E. Inflammasomes: too big to miss. J Clin Invest 2009, 119:3502-3511.
11. Martinon F., Burns K., Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of pro-ILβ. Mol Cell 2002, 10:417-426.
12. Dinarello C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009, 27:519-550.
13. Ting J.P., Willingham S.B., Bergstralh D.T. NLRs at the intersection of cell death and immunity. Nat Rev Immunol 2008, 8:372-379.
14. Petrilli V., Papin S., Dostert C., Mayor A., Martinon F., Tschopp J. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ 2007, 14:1583-1589.
15. Martinon F., Petrilli V., Mayor A., Tardivel A., Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241.
16. Miller Y.I., Choi S.H., Wiesner P., Fang L., Harkewicz R., Hartvigsen K., et al. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res 2011, 108:235-248.
17. Lachmann H.J., Quartier P., So A., Hawkins P.N. The emerging role of interleukin-1B in autoinflammatory diseases. Arthritis Rheum 2011, 63:314-324.
18. Goldbach-Mansky R., Dailey N.J., Canna S.W., Gelabert A., Jones J., Rubin B.I., et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1B inhibition. N Engl J Med 2006, 355:581-592.
19. Larsen C.M., Faulenbach M., Vaag A., Vølund A., Ehses J.A., Seifert B., et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007, 356:1517-1526.
20. Abbate A., Kontos M.C., Grizzard J.D., Biondi-Zoccai G.G., Van Tassell B.W., Robati R., et al. VCU-ART Investigators. Interleukin-1 blockade with Anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial Pilot Study). Am J Cardiol 2010, 105:1371-1377.
21. Persson J., Nilsson J., Lindholm M.W. Interleukin-1beta and tumor necrosis factor-alpha impede neutral lipid turnover in macrophage-derived foam cells. BMC Immunol 2008, 9:70-79.
22. Connat J.L. Inflammasome and cardiovascular diseases. Ann Cardiol Angeiol (Paris) 2011, 60:48-54.
23. Rajamäki K., Lappalainen J., Oörni K., Välimäki E., Matikainen S., Kovanen P.T., et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One 2010, 5:e11765.
24. Duewell P., Kono H., Rayner K.J., Sirois C.M., Vladimer G., Bauernfeind F.G., et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals that form early in disease. Nature 2010, 464:1357-1361.
25. Zhou R., Tardivel A., Thorens B., Choi I., Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 2010, 11:136-140.
26. Olofsson P.S., Sheikine Y., Jatta K., Ghaderi M., Samnegård A., Eriksson P., et al. A functional interleukin-1 receptor antagonist polymorphism influences atherosclerosis development - the interleukin-1β:interleukin-1 receptor antagonist balance in atherosclerosis. Circ J 2009, 73:1531-1536.
27. De Groot P.G., Meijers J.C.M. b2-glycoprotein I: evolution, structure and function. J Thromb Haemost 2011, 9:1275-1284.
28. Kobayashi K., Matsuura E., Liu Q., Furukawa J., Kaihara K., Inagaki J., et al. A specific ligand for β2-glycoprotein I mediates autoantibody-dependent uptake of oxidized low-density lipoprotein by macrophages. J Lipid Res 2001, 42:697-709.
29. Kobayashi K., Kishi M., Atsumi T., Bertolaccini M.L., Makino H., Sakairi N., et al. Circulating oxidized LDL forms complexes with β2-glycoprotein I: implication as an atherogenic autoantigen. J Lipid Res 2003, 44:716-726.
30. Lopez L.R., Salazar-Paramo M., Palafox-Sanchez C., Hurley B.L., Matsuura E., Garcia-De La Torre I. Oxidized low-density lipoprotein and β2-glycoprotein I in patients with systemic lupus erythematosus and increased carotid intima-media thickness: implications in autoimmune-mediated atherosclerosis. Lupus 2006, 15:80-86.
31. Passam F.H., Rahgozar S., Qi M., Raftery M.J., Wong J.W., Tanaka K., et al. Redox control of β2GPI-von Willebrand factor interaction by thioredoxin-1. J Thromb Haemost 2010, 8:1754-1762.
32. Ioannou Y., Zhang J.Y., Passam F.H., Rahgozar S., Qi J.C., Giannakopoulos B., et al. Naturally occurring free thiols with β2-glycoprotein I in vivo: nytrosylation, redox modification by endothelial cells, and regulation of oxidative stress-induced cell injury. Blood 2010, 116:1961-1970.
33. Passam F.H., Giannakopoulos B., Mirarabshahi P., Krillis S.A. Molecular pathophysiology of the antiphospholipid syndrome: the role of oxidative post-translational modification of β2-glycoprotein I. J Thromb Haemost 2011, 9(Suppl. 1):275-282.
34. Ioannou Y., Zhang J.Y., Qi M., Gao L., Qi J.C., Yu D.M., et al. Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen β2-glycoprotein I. Arthritis Rheum 2011, 63:2774-2782.
35. Agar C., van Os G.M., Mörgelin M., Sprenger R.R., Marquart J.A., Urbanus R.T., et al. β2-Glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood 2011, 116:1336-1343.
36. Schattner A., Liang M.H. The cardiovascular burden of lupus; a complex challenge. Arch Intern Med 2003, 163:1507-1510.
37. Kobayashi K., Lopez L.R., Shoenfeld Y., Matsuura E. The role of innate and adaptive immunity to oxidized low-density lipoprotein in the development of atherosclerosis. Ann N Y Acad Sci 2005, 1051:442-454.
38. Frostegard J. Atherosclerosis in patients with autoimmune disorders. Arterioscler Thromb Vasc Biol 2005, 25:1776-1785.
39. Matsuura E., Kobayashi K., Lopez L.R. Preventing autoimmune and infection triggered atherosclerosis for an enduring healthful lifestyle. Autoimmun Rev 2008, 7:214-222.
40. Hasunuma Y., Matsuura E., Makita Z., Katahira T., Nishi S., Koike T. Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997, 107:569-573.
41. Ylä-Herttuala S., Palinski W., Rosenfeld M.E., Parthasarathy S., Carew T.E., Butler S., et al. Evidence for presence of oxidatively modified low-density lipoprotein in atherosclerosis lesions of rabbit and man. J Clin Invest 1989, 84:1086-1095.
42. George J., Harats D., Gilburd B., Afek A., Levy Y., Schneiderman J., et al. Immunolocalization of β2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation 1999, 99:2227-2230.
43. Matsuura E., Kobayashi K., Matsunami Y., Lopez L.R. The immunology of atherothrombosis in the antiphospholipid syndrome: antigen presentation and lipid intracellular accumulation. Autoimmun Rev 2009, 8:500-505.
44. Matsuura E., Kobayashi K., Inoue K., Lopez L.R., Shoenfeld Y. Oxidized LDL/B2-glycoprotein I complexes: new aspects in atherosclerosis. Lupus 2005, 14:736-741.
45. Kajiwara T., Yasuda T., Matsuura E. Intracellular trafficking of β2-glycoprotein I complexes with lipid vesicles in macrophages: implications on the development of antiphospholipid syndrome. J Autoimmun 2007, 29:164-173.
46. Kuwana M., Matsuura E., Kobayashi K., Okazaki Y., Kaburaki J., Ikeda Y., et al. Binding of β2-glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells. Blood 2005, 105:1552-1557.
47. Wang G., Pierangeli S.S., Papalardo E., Ansari G.A.S., Khan M.F. Markers of oxidative and nitrosative stress in systemic lupus erythematosus. Correlation with disease activity. Arthritis Rheum 2010, 62:2064-2072.
48. Lopez L.R., Hurley B.L., Simpson D.F., Matsuura E. Oxidized low-density lipoprotein/B2-glycoprotein I complexes in type 2 diabetes mellitus. Ann N Y Acad Sci 2005, 1051:97-103.
49. Ames P.R.J., Ortiz-Cadenas A., Garcia De La Torre I., Nava A., Oregon-Miranda A., Batuca J.R., et al. Rosuvastatin treatment is associated with a decrease of serum oxidized low-density lipoprotein/B2-glycoprotein I complex concentration in type 2 diabetes. Br J Diabetes Vasc Dis 2010, 10:292-299.
50. Hamid C., Norgate K., D'Cruz D.P., Khamashta M.A., Arno M., Pearson J.D., et al. Anti-β2GPI-antibody-induced endothelial cell gene expression profiling reveals induction of novel pro-inflammatory genes potentially involved in primary antiphospholipid syndrome. Ann Rheum Dis 2007, 66:1000-1007.
51. Ames P.R., Antinolfi I., Ciampa A., Batuca J., Scenna G., Lopez L.R., et al. Primary antiphospholipid syndrome: a low-grade auto-inflammatory disease?. Rheumatology 2008, 47:1832-1837.
52. Tabuchi M., Inoue K., Usui-Kataoka H., Kobayashi K., Teramoto M., Takasugi K., et al. The association of C-reactive protein with an oxidative metabolite of LDL and its implication in atherosclerosis. J Lipid Res 2007, 48:768-781.
53. Greco T.P., Conti-Kelly A.M., Anthony J.R., Greco T., Doyle R., Boisen M., et al. Oxidized-LDL/β2-glycoprotein I complexes are associated with disease severity and increased risk of adverse outcomes in patients with acute coronary syndromes. Am J Clin Pathol 2010, 133:737-743.
54. Okada T., Ayada K., Usui S., Yokota K., Cui J., Kawahara Y., et al. Antibodies against heat shock protein 60 derived from Helicobacter pylori: diagnostic implications in cardiovascular disease. J Autoimmun 2007, 29:106-115.
55. Atzeni F., Turiel M., Hollan I., Meroni P., Sitia S., Tomasoni L., et al. Usefulness of cardiovascular biomarkers and cardiac imaging in systemic rheumatic diseases. Autoimmun Rev 2010, 9:845-848.
56. Sitia S., Tomasoni L., Atzeni F., Ambrosio G., Cordiano C., Catapano A., et al. From endothelial dysfunction to atherosclerosis. Autoimmun Rev 2010, 9:830-834.